Hikma Pharmaceuticals announces launch of argatroban injection

Hikma Pharmaceuticals announced Thursday the US launch of an injection for the treatment of thrombosis in adults.

Hikma Pharmaceuticals announced Thursday the US launch of an injection for the treatment of thrombosis in adults.

The FSTE 250 multinational group is releasing the argatroban injection after receiving approval from the US Food and Drug Administration earlier this year.

The London-based pharmaceutical firm's argatroban is used for the prevention of disease and treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT).

Thrombosis is the formation of a blood clot inside the blood vessel obstructing the flow of blood through the circulatory system. HIT is due to the administration of various forms of heparin, an anticoagulant, and is caused by the formation of abnormal antibodies that activate platelets.

Argatroban will also work as an anticoagulant in preventing the clotting of the blood in adults at risk of HIT undergoing coronary angioplasty, a non-surgical procedure used to treat the stenotic coronary arteries of the heart found in coronary heart disease.

"Hikma is pleased to be bringing argatroban injection to market," Chief Executive Officer of Hikma, Samih Darwazah, said in a statement.

"Argatroban will expand our injectables product line and help to differentiate our product portfolio in the US."

Argatroban injection made approximately $105m in sales for the 12 months ending October 2012, according to IMS Health.

Hikma will be selling the argatroban injection in 100mg/ml vials and was developed through the company's partnership with the speciality pharmaceutical company, Exela Pharma Sciences.

Shares for Hikma, which has a market capitalisation of £1,488.17m, reported a 0.26% drop in shares to 755.00p at 10:15 Thursday.

RD

Recommended

The top funds to invest in
Funds

The top funds to invest in

As market volatility and recessionary fears continue, here are the most popular funds, stocks and trusts investors are putting their money into
2 Mar 2023
The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves takes a look at the companies with the highest dividend yields in the UK’s blue-chip index
27 Feb 2023
The outlook for Shell shares is mixed, despite bumper profits
Energy stocks

The outlook for Shell shares is mixed, despite bumper profits

With profits surging, it looks as if Shell is on a roll, but the company’s growth from here is hard to see as Rupert Hargreaves explains.
6 Feb 2023
The top ten dividend stocks in the FTSE 250
Share tips

The top ten dividend stocks in the FTSE 250

The average FTSE 250 dividend yield is around 4%, but many stocks yield much more. Rupert Hargreaves picks the best FTSE 250 stocks for income investo…
17 Jan 2023

Most Popular

Government plans could see NS&I boost interest rates
Savings

Government plans could see NS&I boost interest rates

The government-backed bank has a new funding target, which could prompt it to boost the rates on its Premium Bonds, ISAs and bonds.
16 Mar 2023
Share tips of the week – 17 March
Investments

Share tips of the week – 17 March

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages
10 Mar 2023
How to make your child a tax-free millionaire by age 37
Investments

How to make your child a tax-free millionaire by age 37

Exclusive research for MoneyWeek reveals how funding an ISA and a pension for your child until age 18 could build up a seven-figure sum by the time th…
14 Mar 2023